We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Virtual Skin Biopsy Determines Presence of Cancerous Cells

By LabMedica International staff writers
Posted on 12 Apr 2024

When dermatologists spot an unusual mark on a patient's skin, they face a choice: monitor it for some time or remove it for biopsy. More...

Similarly, when removing breast tumors, surgeons must send excised tissues to pathologists who take several days to determine if any cancerous cells remain, leading to a second surgery for removing additional cells in about 20% of cases. Pathologists process these tissues by slicing them into thin sections and staining them with hematoxylin and eosin (H&E), which enhances the visibility of cellular structures and is crucial for diagnosing cancers and other diseases. However, this method is labor-intensive and irreversible; once a biopsy is sliced in one direction, it cannot be resectioned for alternative views. Now, a "virtual biopsy" could allow dermatologists to forego the scalpel and scan the skin to check for cancerous cells without an incision. Similarly, surgeons might soon be able to determine if they have completely removed the tumor during the procedure itself by using real-time imaging instead of waiting for traditional pathology results.

Researchers at Stanford Medicine (Stanford, CA, USA) have introduced a technique that utilizes lasers to penetrate tissue and create detailed three-dimensional reconstructions of cellular structures. This method enables the production of cross-sectional images similar to those made by slicing biopsy samples, which are typically examined under a microscope. This breakthrough could allow for noninvasive skin scans and speed up the biopsy results from other tissues, potentially offering more comprehensive diagnostic information. While further development is required to bring this technology to clinical practice, the researchers are optimistic that their innovation will transform how biopsies are performed.

“We’ve not only created something that can replace the current gold-standard pathology slides for diagnosing many conditions, but we actually improved the resolution of these scans so much that we start to pick up information that would be extremely hard to see otherwise,” said Adam de la Zerda, Ph.D., an associate professor of structural biology.

Related Links:
Stanford Medicine


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
HAV Rapid Test
OnSite HAV IgG/IgM Rapid Test
New
STI Test
REALQUALITY RQ-SevenSTI
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A blood-based test aims to address gaps in population-level early cancer detection (Photo courtesy of Harbinger Health)

Blood-Based MCED Test Enables Early-Stage Detection for Multiple Cancer Types

Around 84,000 new cancer cases in the United States each year are thought to arise from obesity, and over the past two decades, the rate of obesity-related cancers has climbed markedly. Thirteen malignancies... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.